1311 related articles for article (PubMed ID: 33381084)
21.
Long X; Liu D; Gao Q; Ni J; Qian L; Ni Y; Fang Q; Jia W; Li H
Front Endocrinol (Lausanne); 2021; 12():773340. PubMed ID: 35035378
[TBL] [Abstract][Full Text] [Related]
22. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Chen Y; Wang W; Morgan MP; Robson T; Annett S
Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
[TBL] [Abstract][Full Text] [Related]
23. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
24. Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.
Karim G; Bansal MB
touchREV Endocrinol; 2023 May; 19(1):60-70. PubMed ID: 37313239
[TBL] [Abstract][Full Text] [Related]
25. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
26. Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.
Liu X; Zhang P; Martin RC; Cui G; Wang G; Tan Y; Cai L; Lv G; Li Y
Am J Cancer Res; 2016; 6(5):1011-25. PubMed ID: 27293995
[TBL] [Abstract][Full Text] [Related]
27. Nonalcoholic Steatohepatitis: A Review.
Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
[TBL] [Abstract][Full Text] [Related]
28. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
29. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Tacke F; Weiskirchen R
Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
[TBL] [Abstract][Full Text] [Related]
30. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
31. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.
Bao L; Yin J; Gao W; Wang Q; Yao W; Gao X
Br J Pharmacol; 2018 Aug; 175(16):3379-3393. PubMed ID: 29859019
[TBL] [Abstract][Full Text] [Related]
32. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
33. Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis.
Ye X; Chen Y; Qi J; Zhu S; Wu Y; Xiong J; Hu F; Guo Z; Liang X
Eur J Pharmacol; 2023 Aug; 952():175811. PubMed ID: 37245859
[TBL] [Abstract][Full Text] [Related]
34. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis.
Verzijl CRC; Van De Peppel IP; Struik D; Jonker JW
Expert Opin Investig Drugs; 2020 Feb; 29(2):125-133. PubMed ID: 31899984
[No Abstract] [Full Text] [Related]
35. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
36. Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis.
Chung KW; Cho YE; Kim SJ; Hwang S
Arch Pharm Res; 2022 Apr; 45(4):229-244. PubMed ID: 35391713
[TBL] [Abstract][Full Text] [Related]
37. Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling.
Lan T; Hu Y; Hu F; Li H; Chen Y; Zhang J; Yu Y; Jiang S; Weng Q; Tian S; Ma T; Yang G; Luo D; Wang L; Li K; Piao S; Rong X; Guo J
J Hepatol; 2022 Feb; 76(2):407-419. PubMed ID: 34656650
[TBL] [Abstract][Full Text] [Related]
38. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.
Berardo C; Di Pasqua LG; Cagna M; Richelmi P; Vairetti M; Ferrigno A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348908
[TBL] [Abstract][Full Text] [Related]
40. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
Sundaram V; Morgan TR
Clin Liver Dis; 2019 Feb; 23(1):157-165. PubMed ID: 30454829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]